Hope in Motion: The Future of Parkinson’s Clinical Trials in Australia and New Zealand

In a recent presentation, Dr. Alex Lyn, a neurologist at the Princess Alexandra Hospital in Brisbane and chair of the MDS ANZ Clinical Trials Network (CTN), shared a comprehensive update on the landscape of movement disorder research. Highlighting a shift toward making Australia and New Zealand key destinations for global research, Dr. Lyn detailed three groundbreaking trials currently underway or launching soon, ranging from genetic targeting to regenerative medicine. Understanding the Process: Clinical Trial Phases To understand where these new treatments stand, Dr. Lyn clarified the distinct stages of clinical research: Phase 1: These are the first clinical studies, often performed on healthy controls. The primary goal is not to check if the drug works, but to ensure safety and tolerability. Phase 2: This stage involves patients with the specific disease (typically 50–300 participants). Researchers begin looking for an actual effect on the disease alongside side effect profiles. Phase 3: These are large-scale, randomized, placebo-controlled trials. A drug must pass Phase 3 to be registered for general use by the FDA or TGA. 1. The GAIN Trial: Targeted Genetic Therapy Dr. Lyn emphasized the need to move away from a "one-size-fits-all" approach to Parkinson's treatment. The GAIN trial represents the future of "tailored therapy," specifically targeting patients with mutations in the GBA1 gene. The Mechanism: The GBA1 gene codes for a protein called glucocerebrosidase, a lysosomal enzyme responsible for clearing cellular debris. In 5–7% of Parkinson's patients, a mutation causes this cleaning mechanism to fail, leading to debris buildup and mitochondrial dysfunction. The Drug: This trial tests a small molecule designed to restore the function of the glucocerebrosidase protein. Status: A Phase 1 trial looking at safety has just concluded in Australia with positive feedback from the company. A Phase 2 study looking at effectiveness is expected to begin in mid-2026. 2. Stem Cell Therapy: Restoring Lost Function Perhaps the most anticipated update is a new Phase 3 stem cell trial. While early 2000s stem cell trials failed, Dr. Lyn notes that this new wave is built on 20 years of lessons learned. The Results: This trial follows a Phase 1 study of 12 patients where the outcome was described as "mind-boggling". Patients showed a 17.9-point improvement in their MDS-UPDRS (severity score) which was maintained over a three-year follow-up. The Procedure: This is a surgical trial operating in the US, Canada, and Australia. It is a "sham surgery" controlled study, meaning participants have a 2-in-3 chance of receiving the cells and a 1-in-3 chance of receiving a placebo surgery. However, placebo patients may be offered the real treatment after 18 months if the therapy works. Eligibility: To qualify, patients must respond to dopamine therapy, and cannot have dementia, recurrent falls, or existing advanced therapies like Deep Brain Stimulation (DBS). 3. Polymer-Linked Apomorphine: New Delivery for Old Drugs The third trial addresses the "short half-life" of current Parkinson's medications, which often requires patients to take pills multiple times a day or use cumbersome pumps. The Innovation: This trial uses Apomorphine (a standard drug) linked to a polymer (a large chemical structure). The Benefit: This formulation allows the drug to be injected under the skin just twice a week, slowly diffusing into the system over several days. This eliminates the need for daily pumps or frequent dosing. Status: This is a Phase 1b trial expected to start in early 2026. Requirement: Participants must be willing to stay in the hospital for 7 days for precise monitoring. Looking Ahead Dr. Lyn expressed optimism for the future, noting that further trials involving immunotherapies (using antibodies to clear abnormal proteins) and additional stem cell therapies are expected to arrive in Australia over the next 18 months. For patients and families interested in participating, Dr. Lyn urges them to get excited about research and connect with their local clinicians or the Clinical Trials Network coordinator, Ann Norton.